ABEO - Abeona Therapeutics Inc
Abeona Therapeutics Inc Logo

ABEO - Abeona Therapeutics Inc

https://www.abeonatherapeutics.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.

52W High
$7.54
52W Low
$3.93
MA Status:
50D: Below 200D: Above
Beta (~1 neutral, <0.9 lower risk)
1.67
Valuation
Fair
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
10.20
Forward P/E (<15 better)
22.94
EV/EBITDA (<8 favorable)
1.67
EV/Revenue (<3 favorable)
333.52
P/S (TTM) (<3 favorable)
837.12
P/B (<3 favorable)
2.05
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
5.78%
Institutions (25–75% balanced)
73.56%
Shares Outstanding
51,278,000
Float
38,195,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
400,000
Gross Profit (TTM)
-33,519,000
EPS (TTM)
0.64
Profit Margin (>10% good)
143.10%
Operating Margin (TTM) (higher better)
-56.98%
ROE (TTM) (>15% strong)
0.48%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
-0.0117
Previous
0.0293
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025